CADTH Canadian Drug Expert Committee recommendation: Risankizumab (Skyrizi -- Abbvie) indication : adult patients with moderate to severe plaque psoriasis
The CADTH Canadian Drug Expert Committee (CDEC) recommends that risankizumab be reimbursed for the treatment of moderate to severe plaque psoriasis in adults only if the following conditions are met: In a manner similar to other biologics reimbursed for the treatment of moderate to severe plaque pso...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
May 2019, 2019
|
| Edition: | Version 1.0. (final) |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that risankizumab be reimbursed for the treatment of moderate to severe plaque psoriasis in adults only if the following conditions are met: In a manner similar to other biologics reimbursed for the treatment of moderate to severe plaque psoriasis. Treatment should be discontinued if a response to risankizumab has not been demonstrated by 16 weeks. The drug plan cost for risankizumab should not exceed the drug plan cost of treatment with the least costly biologic therapy reimbursed for the treatment of moderate to severe plaque psoriasis |
|---|---|
| Physical Description: | 1 PDF file (9 pages) |